Stocks-SGMO-Sangamo Therapeutics Inc

SGMO Sangamo Therapeutics Inc

2.84 0.06 (2.16%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

Overview

Prev Close 2.84
Day's Range 2.65 - 3.15
52 Week Range 0.2700 - 3.15
Average Volume (3M) 7.23M
1-Year Return 683.02%
Beta1.6673
Market Cap 585.1M
P/E Ratio-2.04
Revenue12.28M
EPS-1.3767
Dividend (Yield) 0 (0%)
Industry
Biotechnology
CEO
Alexander D. Macrae, PhD
Employees
405

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2023: Sangamo Therapeutics Inc's revenues increased by 58.34% and amounted to 176.23M. Net income decreased by 34.09% to -257.83M. Net assets decreased by NaN to N/A and EPS decreased from -1.25 to -1.48.
SGMO's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Created with Highcharts 4.2.7 /Highstock 4.2.7Total RevenueNet Income09/2312/2303/2406/24-125M-100M-75M-50M-25M025M
Gross Margin
-43.29%
Net Profit Margin
-135.08%
Operating Margin
-1,663.90%
Return On Investment
-72.85%
09/23
12/23
03/24
06/24
Total Revenue
9.4M
2.04M
481K
356K
Gross Profit
-113K
-940K
-2.05M
-2.22M
Operating Income
-61.61M
-61.76M
-45.38M
-34.04M
Net Income
-104.16M
-60.3M
-49.09M
-36.13M